(no supplement) were consumed an order randomly assigned using www.randomizer.org. The 123 condition randomized to was concealed by providing participants with ready prepared jelly (Jell-O) 124 and mousse containing the supplement or control (no supplement) to disguise the treatment. Each 125 study period comprised a 6-d run-in with a study day at the CIU on Day 7 and were separated by a 126 washout period of ≥1-wk. Prior to commencing the study, all participants who had not previously 127 participated in an appetite study attended an initial study morning at the CIU to familiarise with the 128 techniques being used. To control for effects of hormonal variations throughout the menstrual cycle be consumed alongside participants' usual diet. Sugar free jelly was chosen as the vehicle to 143 provide the supplement, as it did not contribute greatly to the EI, it disguised the supplement or 144 control, and made it easy for the participant to consume the supplement, as no additional 145 preparation was required. The jellies were collected by or were dropped off to participants every 146 few days. Compliance, gastrointestinal symptoms and the taste of the jellies were assessed using a 147 daily monitoring diary, and a 4-day food diary was completed from Days 3 to 6 using household 148 measures. Gastrointestinal symptoms (stomach pain, diarrhoea, constipation, belching, flatulence, 149 nausea, acid regurgitation, heartburn and bloating) were monitored on a five point scale (1: none, 3: 150 moderate, 5: debilitating), and taste was assessed on a nine point Likert Scale.. 151
152

Study day (Day 7) 153
Participants arrived at the CIU in a fasted state after consuming a standard low fiber meal the 154 previous evening and avoiding alcohol and unaccustomed exercise for 24-h. Participants wereM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 required to stay in the CIU for the entire study duration and water was provided ad libitum. Upon 156 arrival anthropometric measurements were taken and an intravenous cannula was inserted into an 157 antecubital vein. Two fasting blood samples were taken 30 min and 5 min before breakfast, and 158 hydrogen concentrations in expired breath were measured using a Gastrolyser 2 portable hand held 159 breath hydrogen monitor (Bedfont Scientific Ltd, Rochester, UK). Following each baseline blood 160 and breath sample appetite was subjectively assessed by 100 mm visual analogue scale (VAS) 161 questionnaires for fullness, hunger, prospective food consumption, desire to eat meal / snack / sweet 162 / savoury / salty / fatty and nausea as previously described (Flint, Raben, Blundell, & A., 2000) . 163
Gastrointestinal symptoms (flatulence, diarrhoea, bloating, belch/burp, stomach discomfort, urge to 164 defacate and heartburn) were also assessed by 100 mm VAS following the first baseline blood 165 sample. 166
A standard mixed breakfast and lunch (described below) were provided at t=0 min and 167 t=180 min, and consumed within 15 min. A mousse was provided alongside breakfast and lunch 168 containing two-thirds and one-third of the daily target supplement dose, respectively, or no 169 supplement (control). The taste of the mousse was rated after each meal using 100mm VAS. 170
Following each meal blood was sampled every 15 min for the first hour, then half-hourly, VAS 171 were completed after blood samples to assess appetite half-hourly and to assess gastrointestinal 172 symptoms hourly. Breath was sampled hourly for the first hour and half-hourly thereafter. 173
The cannula was removed at t=420 min (240 min following lunch) after which participants 174 were seated in individual booths at t=420 min and served an ad libitum homogenous pasta meal in a 175 quantity exceeding usual portion sizes and instructed to eat until they were "comfortably full", as 176 previously conducted by our group (Bodinham, 339.1 g carbohydrate, 70.0 g fat and 15.9 g fiber and had a mean weight of 1520 ± 53 g and energy 214 density of 6.4 ± 0.2 kJ/g. The weight and energy density varied due to differing amounts of water 215 absorbed by the pasta during cooking which was accounted for when calculating EI. The dish was 216 weighed before and after serving to determine intake. 217
218
Biochemistry 219
Venous blood samples were centrifuged at 1750 g for 10 min and plasma aliquots were stored at -20 220 °C until analysis. Samples were batch analysed with samples from the same participant in the same 221 batch to minimise inter-assay variability. Plasma glucose, TG, non-esterified fatty acids (NEFA) 222 and total and HDL cholesterol concentrations were measured using commercial kits for the ILAB 223 650 analyzer (Instrumentation Laboratory, Milan, Italy), with an inter-assay CV of <2 %. Plasma 224 insulin concentrations were analyzed by radioimmunoassay using a commercial kit (Millipore, St. 225
Charles, Missouri), with an inter-and intra-assay CV <10 %. Serum SCFA were analyzed by gas 226 chromatography as previously described (Bodinham, et kg/m 2 and 1.1 to 3.6 respectively completed the study. Of the eight female participants, seven were 268 using birth control medication ( Table 1) 
Quantitative appetite assessment 272
No differences between treatments were found for mean daily energy and macronutrient intake 273 during the days 3 to 6 of the run-in period, or for 24-h dietary intake on the study day ( Table 2) . 274
Mean ad libitum EI of the homogenous pasta meal served at 420 min on the study day did not differ 275 between control, inulin or L-Rha (4202 ± 1666, 4089 ± 1680 and 4053 ± 1538 kJ respectively). No treatment or treatment x time interactions or differences between AUC or iAUC were found 305 postprandially and no differences between fasting concentrations were found between treatments 306 for propionate, acetate or butyrate (Figure 3) . 307
308
Insulin sensitivity 309
Neither fasting insulin sensitivity, cell function and insulin resistance as estimated by HOMA nor 310 postprandial insulin sensitivity estimated using the minimal model method were found to differ 311 between treatments (data not shown). 312
313
Gastrointestinal symptoms 314
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
During run-in, the mean daily flatulence ratings during days 4 to 6 (when participants were 315 consuming the target dose of supplement) were significantly influenced by treatment (χ 2 (2) = 8.6, P 316 = 0.014). Scores were significantly higher during inulin treatment than control (T = 36, r = -0.40, 317 P=0.012) and L-Rha (T = 6, r = -0.35, P=0.028), with mean scores of 2.2 ± 0.9, 1.4 ± 0.6 and 1.5 ± 318 0.5 respectively. On the study day (day 7), the AUC for the urge to defacate was significantly 319 higher during L-Rha treatment than control (T = 84, r = -0.43, P =0.007) (data not shown). None of 320 the other gastrointestinal symptoms was significantly influenced by treatment during run-in or on 321 the study day. 322
323
Taste ratings 324
Mean daily ratings of the taste of the jellies supplied during the run-in period did not differ between 325 treatments. On the study day, treatment significantly influenced the rated taste of the mousse at 326 breakfast (F(2,24) = 5.49, P=0.011), with the lowest VAS score for L-Rha, followed by inulin and 327 the highest for control (58 ± 21, 73 ± 20 and 75 ± 21 mm respectively), but not at lunch. investigate effects on long-chain inulin. Indeed in the present study we found that gastrointestinal 374 symptoms were not adversely affected by long-chain inulin supplementation, except significantly 375 higher flatulence scores during run-in, and even then the mean flatulence symptom score with inulin 376 treatment of 2.2 ± 0.9 (scored on a 9-point Likert Scale) remained relatively low. 377
We did not find any significant effects of supplementation with long-chain inulin on 378 qualitative or quantitative appetite measures, on postprandial metabolites or on serum SCFA 379 concentrations. The lack of effect on postprandial serum SCFA in conjunction with a higher breath 380 hydrogen response has been previously reported following consumption of long-chain inulin 381 (Fernandes, et al., 2011) . In common with our findings, a previous trial in 22 unrestrained females 382 found acute ingestion of 10 g long-chain inulin within a chocolate crisp bar did not alter qualitative 383 or quantitative appetite measures in comparison to a control bar (Karalus, et al., 2012) . By contrast 384 24 g long-chain inulin used as a fat-replacer in sausage patties significantly reduced 24-h EI in 385 comparison to a full fat patty in an acute meal challenge in healthy participants (n=33), although 386 rated satiety was not altered, and ad libitum EI was not investigated (Archer, et al., 2004) . However,M A N U S C R I P T
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18 interpretation difficult (Archer, et al., 2004) . In our study the control was energy and macronutrient 389 matched to the investigative products. Higher plasma GLP-1 concentrations at 30 min and reduced 390 ghrelin concentrations at 270 and 360 min were reported following an acute meal challenge in 12 391 healthy participants with 24 g inulin plus 56 g high-fructose corn syrup in comparison to 56 g high-392
fructose corn syrup and 80 g high-fructose corn syrup mixed into a drink (Tarini & Wolever, 2010) . 393
However as effects on GLP-1 were seen so early on postprandially this is suggestive the 394 observation is not linked to colonic fermentation. Overall the evidence does not strongly support a 395 role for long-chain inulin in influencing appetite, although studies are limited by participant 396 numbers. 397
The majority of previous studies investigating metabolic effects of long-chain inulin have 398 investigated fasting rather than postprandial effects, therefore there is a paucity of comparative 399 studies. In an acute meal challenge, glucose and insulin responses did not differ significantly 400 following supplementation with 24 g inulin + 56g high-fructose corn syrup mixed into a drink in 401 comparison to 56 g and 80 g high-fructose corn syrup in healthy participants (n=12) (Tarini & The present study had a number of limitations which need to be acknowledged when 408 interpreting findings. Ideally the study would have been double blinded, however as there was only 409 a single investigator (JD) to conduct the study this was not possible. The study included relatively 410 few participants, however effects on food intake were so negligible retrospective power analysis 411 suggested 250 participants would be required for statistical significance, which is far greater than in 412 other studies of this nature. Thus the lack of effect is likely due to a lack of biological effect rather 413 M A N U S C R I P T
19 than simply a power issue. We chose to include female participants in order to be more 414 representative of the general population. However whilst every effort was made to control for 415 hormonal fluctuations, this will likely have added some variability. Participants were informed of 416 the broad purpose of the study, which may have impacted behavior, however every effort was made 417 to maintain a uniform protocol for each condition. We did not assess if participants were aware of 418 the study hypotheses or if they were able to accurately report any differences in the protocol 419 according to the condition they were randomised to. As water was supplied ad libitum to be more 420 reflective of free-living conditions, this may have impacted on appetite, an effect we could not 421 assess as water intake was not measured. 422
In conclusion, the present investigation found neither inulin HP nor L-Rha influenced 423 appetite, and inulin HP did not influence postprandial metabolic responses. However L-Rha 424 appeared to inhibit postprandial insulin secretion and also NEFA, possibly via propionate-mediated 425 colonic FFAR2 and/or FFAR3 actions, although serum propionate was not significantly altered and 426 insulin was not inhibited following ingestion of propionate tethered to inulin. This suggests that the 427 mechanism underlying our findings may not be mediated by propionate as originally hypothesized, 428 which warrants further investigation. 429
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